Assessment of eight HPV vaccination programs implemented in lowest income countries

被引:87
作者
Ladner, Joel [1 ]
Besson, Marie-Helene [2 ]
Hampshire, Rachel [3 ]
Tapert, Lisa [3 ]
Chirenje, Mike [4 ]
Saba, Joseph [2 ]
机构
[1] Rouen Univ Hosp, Hop Charles Nicolle, Dept Epidemiol & Publ Hlth, F-76031 Rouen, France
[2] Axios Int, F-75001 Paris, France
[3] Axios Healthcare Dev, Cleveland, OH USA
[4] Univ Zimbabwe, Harare, Zimbabwe
关键词
HPV vaccination; Cervical cancerp; Low and middle-income countries; Vaccine delivery; Program evaluation; HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; PARTICLE VACCINE; PREVENTION; ACCEPTABILITY; EFFICACY;
D O I
10.1186/1471-2458-12-370
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Cervix cancer, preventable, continues to be the third most common cancer in women worldwide, especially in lowest income countries. Prophylactic HPV vaccination should help to reduce the morbidity and mortality associated with cervical cancer. The purpose of the study was to describe the results of and key concerns in eight HPV vaccination programs conducted in seven lowest income countries through the Gardasil Access Program (GAP). Methods: The GAP provides free HPV vaccine to organizations and institutions in lowest income countries. The HPV vaccination programs were entirely developed, implemented and managed by local institutions. Institutions submitted application forms with institution characteristics, target population, communication delivery strategies. After completion of the vaccination campaign (3 doses), institutions provided a final project report with data on doses administered and vaccination models. Two indicators were calculated, the program vaccination coverage and adherence. Qualitative data were also collected in the following areas: government and community involvement; communication, and sensitization; training and logistics resources, and challenges. Results: A total of eight programs were implemented in seven countries. The eight programs initially targeted a total of 87,580 girls, of which 76,983 received the full 3-dose vaccine course, with mean program vaccination coverage of 87.8%; the mean adherence between the first and third doses of vaccine was 90.9%. Three programs used school-based delivery models, 2 used health facility-based models, and 3 used mixed models that included schools and health facilities. Models that included school-based vaccination were most effective at reaching girls aged 9-13 years. Mixed models comprising school and health facility-based vaccination had better overall performance compared with models using just one of the methods. Increased rates of program coverage and adherence were positively correlated with the number of vaccination sites. Qualitative key insights from the school models showed a high level of coordination and logistics to facilitate vaccination administration, a lower risk of girls being lost to follow-up and vaccinations conducted within the academic year limit the number of girls lost to follow-up. Conclusion: Mixed models that incorporate both schools and health facilities appear to be the most effective at delivering HPV vaccine. This study provides lessons for development of public health programs and policies as countries go forward in national decision-making for HPV vaccination.
引用
收藏
页数:8
相关论文
共 25 条
[11]   Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review [J].
Louie, Karly S. ;
de Sanjose, Silvia ;
Mayaud, Philippe .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2009, 14 (10) :1287-1302
[12]   Epidemiologic classification of human papillomavirus types associated with cervical cancer [J].
Muñoz, N ;
Bosch, FX ;
de Sanjosé, S ;
Herrero, R ;
Castellsagué, X ;
Shah, KV ;
Snijders, PJF ;
Meijer, CJLM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :518-527
[13]   Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial [J].
Paavonen, Jorma ;
Jenkins, David ;
Bosch, F. Xavier ;
Naud, Paulo ;
Salmeron, Jorge ;
Wheeler, Cosette M. ;
Chow, Song-Nan ;
Apter, Dan L. ;
Kitchener, Henry C. ;
Castellsague, Xavier ;
de Carvalho, Newton S. ;
Skinner, S. Rachel ;
Harper, Diane M. ;
Hedrick, James A. ;
Jaisamrarn, Unnop ;
Limson, Genara A. M. ;
Dionne, Marc ;
Quint, Wim ;
Spiessens, Bart ;
Peeters, Pascal ;
Struyf, Frank ;
Wieting, Susan L. ;
Lehtinen, Matti O. ;
Dubin, Gary .
LANCET, 2007, 369 (9580) :2161-2170
[14]   Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women [J].
Paovonen, J. ;
Naud, P. ;
Salmeron, J. ;
Wheeler, C. M. ;
Chow, S-N ;
Apter, D. ;
Kitchener, H. ;
Castellsague, X. ;
Teixeira, J. C. ;
Skinner, S. R. ;
Hedrick, J. ;
Jaisamrarn, U. ;
Limson, G. ;
Garland, S. ;
Szarewski, A. ;
Romanowski, B. ;
Aoki, F. Y. ;
Schwarz, T. F. ;
Poppe, W. A. J. ;
Bosch, F. X. ;
Jenkins, D. ;
Hardt, K. ;
Zahaf, T. ;
Descamps, D. ;
Struyf, F. ;
Lehtinen, M. ;
Dubin, G. .
LANCET, 2009, 374 (9686) :301-314
[15]   Strategies to vaccinate against cancer of the cervix: Feasibility of a school-based HPV vaccination program in Peru [J].
Penny, Mary ;
Bartolini, Rosario ;
Rocio Mosqueira, N. ;
Scott LaMontagne, D. ;
Ana Mendoza, Maria ;
Ramos, Irma ;
Winkler, Jennifer L. ;
Villafana, Jose ;
Janmohamed, Amynah ;
Jumaan, Aisha O. .
VACCINE, 2011, 29 (31) :5022-5030
[16]   Qualitative research in health care - Analysing qualitative data (Reprinted from Qualitative Research in Health Care) [J].
Pope, C ;
Ziebland, S ;
Mays, N .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7227) :114-116
[17]   Education, training, and communication for HPV vaccines [J].
Sherris, Jacqueline ;
Friedman, Allison ;
Wittet, Scott ;
Davies, Philip ;
Steben, Marc ;
Saraiya, Mona .
VACCINE, 2006, 24 :210-218
[18]   Evaluating human papillomavirus vaccination programs [J].
Taira, AV ;
Neukermans, CP ;
Sanders, GD .
EMERGING INFECTIOUS DISEASES, 2004, 10 (11) :1915-1923
[19]   High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up [J].
Villa, L. L. ;
Costa, R. L. R. ;
Petta, C. A. ;
Andrade, R. P. ;
Paavonen, J. ;
Iversen, O-E ;
Olsson, S-E ;
Hoye, J. ;
Steinwall, M. ;
Riis-Johannessen, G. ;
Andersson-Ellstrom, A. ;
Elfgren, K. ;
von Krogh, G. ;
Lehtinen, M. ;
Malm, C. ;
Tamms, G. M. ;
Giacoletti, K. ;
Lupinacci, L. ;
Railkar, R. ;
Taddeo, F. J. ;
Bryan, J. ;
Esser, M. T. ;
Sings, H. L. ;
Saah, A. J. ;
Barr, E. .
BRITISH JOURNAL OF CANCER, 2006, 95 (11) :1459-1466
[20]  
Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741